ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Arkuda Therapeutics has raised $64 million in series B financing to develop small molecules that treat neurodegenerative diseases, including GRN-related frontotemporal dementia (FTD-GRN). The firm’s strategy is to boost levels of a protein called progranulin, which is deficient in people with FTD-GRN. Arkuda was founded in 2018 by CEO Gerhard Koenig, the medicinal chemist Duane Burnett, and Bruce Booth of Atlas Venture. Investors in the new funding round include Atlas, Eli Lilly and Company, and Pfizer Ventures.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X